Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)

SD-101 (Zorblesia™)Positive

AI Analysis

Summary

Paradigm Therapeutics received a second consecutive nomination for the 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a topical therapy for treating epidermolysis bullosa across all subtypes.

Importance:3/10

Sentiment:

0.60

award nominationtopical therapyepidermolysis bullosadermatology

Related Companies

$SURF $TRAX

Read the original article

Published by PR Newswire Biotech on October 13, 2026 7:36 PM

Read Original